# A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma

> **NCT02783599** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 51 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Olaratumab
- **DRUG:** Doxorubicin
- **RADIATION:** External Beam Radiotherapy

## Key facts

- **NCT ID:** NCT02783599
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-11
- **Primary completion:** 2018-07-05
- **Final completion:** 2018-07-05
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2019-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02783599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02783599, "A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02783599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*